Compare Citius Pharmaceuticals Inc (CTXR) vs International Business Machines Corp (IBM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs International Business Machines Corp — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while International Business Machines Corp trades at $226.44 (market cap $213.50B). The key difference: International Business Machines Corp is far larger — about 15675.5× Citius Pharmaceuticals Inc's market cap, and International Business Machines Corp pays a 2.98% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and International Business Machines Corp for 88 Days on average.
| CTXR | IBM | |
|---|---|---|
Market Cap | $13.62M | $213.50B |
Volume | 132,438 | 8,908,687 |
Sector | Health | Technology |
52-Week High | $1.82 | $329.23 |
52-Week Low | $0.48 | $205.77 |
Typical Hold Time | 16 Days | 88 Days |
Enterprise Value | $3.79M | $270.64B |
Dividend Yield | — | 2.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
IBM's stock trades at $220.51, down 0.35% on the day, amid a bearish technical signal. The company reported strong 2025 results with revenue of $67.54B and net income of $10.59B, beating earnings expectations in recent quarters. Analyst consensus is a Buy with a $256.69 price target, though technical indicators show resistance near $222. Recent news highlights IBM's focus on AI, including self-hosted deployment for its Bob platform.
IBM presents a mixed outlook with solid fundamentals and AI growth potential offset by near-term technical weakness and competitive pressures. The stock's valuation appears reasonable with a P/E of 19.58, but investors face risks from execution challenges and market volatility. Upside hinges on sustained earnings growth and successful AI integration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About International Business Machines Corp
International Business Machines Corporation (IBM) provides computer solutions. The Company offers application, technology consulting and support, process design and operations, cloud, digital workplace, and network services, as well as business resiliency, strategy, and design solutions. IBM serves clients worldwide.
Read more on IBM →
